Amgen buys cancer drugmaker for $10.4B

08/26/2013 | Reuters

Amgen agreed to acquire Onyx Pharmaceuticals for $125 per share, or around $10.4 billion, in the fifth-largest biotechnology deal ever. The agreement will give Amgen rights to several cancer drugs, including the multiple myeloma drug Kyprolis, liver and kidney cancer treatment Nexavar, and colon cancer drug Stivarga. The acquisition is expected to be finalized this year.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX